AI|ffinity s.r.o.

AI|ffinity, founded in late 2021 as a spin-off from Masaryk University and supported by the Central European Institute of Technology (CEITEC), is a company specializing in creating innovative solutions for the pharmaceutical and biotechnology industries. By harnessing the power of NMR, AI, and Cheminformatics, AI|ffinity focuses on quantifying protein-ligand binding affinity for hit discovery and lead optimization, characterizing protein-ligand interactions, and determining protein 3D structures. Operating from its headquarters in Brno (NMR hub), Czech Republic, with additional facilities in Prague (CADD hub), AI|ffinity aims to expedite the initial phases of drug discovery, improve success rates, and reduce costs by eliminating unnecessary experiments. Its comprehensive NMR-AI platform covers the entire target-to-lead process, while its 4D NMR-AI technology finds applications in drug design and protein engineering.